Atridox (doxycycline hyclate) / Tolmar - LARVOL DELTA

Mathematical Modeling of Local Drug Delivery in the Oral Cavity: From Release Kinetics to Mini-PBPK and Local PK/PD with Applications to Periodontal Therapies. (PubMed, Pharmaceutics) - "The proposed mini-PBPK framework bridges empirical release data and physiological transport in the oral cavity. It supports rational formulation design, optimisation of local dosage, and personalised prediction of drug retention in gingival pockets. This modelling approach can become a practical tool for the development of dental biomaterials and subgingival therapies."

Journal • PK/PD data • Review • Inflammation

Does prophylactic application of doxycycline at the implant-abutment interface improve clinical outcomes of dental implants? (PubMed, Evid Based Dent) - "Design Randomised controlled clinical trial.Data sources Not applicable.Study aims This split-mouth randomised controlled clinical trial assessed the effects of placing doxycycline hyclate (Atridox) at the implant-abutment interface on the short-term clinical outcomes of dental implants.Methods The study sample included 20 patients; each patient had two mandibular implants placed, one on either side of the mandible, resulting in a total of 40 implants placed in the study sample. Marginal bone levels and pocket probing depths after 6 and 12 months on the test side were less compared to the control side and these differences were statistically significant. The test side also showed fewer implants with bleeding on probing and lower risk of peri-implant mucositis after 3, 6 and 12 months.Conclusion Prophylactic placement of doxycycline hyclate may reduce peri-implant bone loss and pocket probing depths, and may also reduce the risk of peri-implant mucositis."

Clinical • Clinical data • Journal • Review • Mucositis • Osteoporosis

Doctors turn to antibiotics after sex in fight against syphilis surge (Financial Times) - "The CDC said it was 'excited' by the initial findings of the UCSF study, which was funded by the National Institutes for Health. But Leandro Mena...said the agency wanted to review the full data and consider the issue of anti-microbial resistance before issuing formal guidance to doctors....'If we could have a vaccine that could effectively reduce the risk of getting these infections. You know that would be the Holy Grail,' Mena added."

Media quote

Modification of Small Dissolution Chamber System for Long-acting Periodontal Drug Product Evaluation. (PubMed, Int J Pharm) - "Three periodontal drug products with different dosage forms were tested: Atridox, Arestin, and PerioChip...For dose discrimination between 75% and full dosing, significant differences were observed in the drug release data at specific time points of the products (p ≤ 0.05). The present results suggest that a small volume dissolution chamber with slow flow rate could potentially provide biologically relevant and dose-discriminating evaluations for periodontal drug products."

Journal